Search Results - "Kermeen, F.D"

  • Showing 1 - 18 results of 18
Refine Results
  1. 1
  2. 2

    Resolution of Severe Ischemia–Reperfusion Injury Post–Lung Transplantation After Administration of Endobronchial Surfactant by Kermeen, F.D., MD, McNeil, K.D., MD, Fraser, J.F., MD, McCarthy, J., MD, Ziegenfuss, M.D., MD, Mullany, D., MD, Dunning, J., MD, Hopkins, P.M., MD

    “…Background Ischemia–reperfusion injury (IRI) is a prominent cause of primary graft failure after lung transplantation and is associated with an altered…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5

    Safety of a Mesenchymal-Like Adherent Stromal Cell (PLX-PAD) in a Human Model of Pulmonary Arterial Hypertension (PAH) by Chambers, D.C, Hunt, W, Naidoo, R, Wall, D, Choudhary, J, Enever, D.L, Samson, L, Yerkovich, S.T, Rapchuk, I.L, Smith, I.J, Hopkins, P.M.A, Kermeen, F.D

    “…Purpose A gap remains between the evidence for safety provided by PAH animal models and that needed to commence early phase human studies, particularly for…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Endothelin Receptor Antagonists are an Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease With or Without Trisomy 21 by Kermeen, F.D., FRACP, Franks, C., RN, O’Brien, K., RN, Seale, H., B.Pthy, Hall, K., B.Pthy, McNeil, K., FRACP, Radford, D., FRACP

    Published in Heart, lung & circulation (01-10-2010)
    “…Introduction Traditionally, treatment options for patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) are limited…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18